FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…